Volume | 17,447,598 |
|
|||||
News | - | ||||||
Day High | 41.675 | Low High |
|||||
Day Low | 41.07 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
41.54 | 41.07 | 41.675 | 41.24 | 41.54 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
114,930 | 17,447,598 | US$ 41.38 | US$ 721,899,828 | - | 41.07 - 66.69 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:44 | 13 | US$ 41.25 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
83.4B | 2.02B | - | 45.01B | 8.03B | 3.97 | 10.39 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 44.34 | 44.34 | 41.07 | 42.71 | 14,442,511 | -3.06 | -6.90% |
1 Month | 44.73 | 45.715 | 41.07 | 43.92 | 13,882,595 | -3.45 | -7.71% |
3 Months | 50.93 | 55.035 | 41.07 | 49.04 | 15,778,004 | -9.65 | -18.95% |
6 Months | 49.75 | 55.035 | 41.07 | 49.70 | 15,400,884 | -8.47 | -17.03% |
1 Year | 66.60 | 66.69 | 41.07 | 53.53 | 13,269,485 | -25.32 | -38.02% |
3 Years | 67.23 | 81.435 | 41.07 | 63.12 | 11,637,445 | -25.95 | -38.60% |
5 Years | 47.40 | 81.435 | 41.07 | 60.90 | 12,297,078 | -6.12 | -12.91% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |